Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2010-03, Vol.24 (3), p.658-660
Hauptverfasser:	Hiwase, D K, White, D, Zrim, S, Saunders, V, Melo, J V, Hughes, T P
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use ATP Binding Cassette Transporter, Subfamily B ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors Biological and medical sciences Cancer Research Chronic myeloid leukemia Critical Care Medicine Dasatinib Dosage and administration Drug Synergism Drug therapy Drug therapy, Combination Health aspects Hematologic and hematopoietic diseases Hematology Humans Intensive Internal Medicine K562 Cells letter-to-the-editor Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Medicine Medicine & Public Health Nilotinib Oncology Protein Kinase Inhibitors - administration & dosage Pyrimidines - administration & dosage Pyrimidines - pharmacokinetics Pyrimidines - pharmacology Thiazoles - administration & dosage Thiazoles - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!